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We studied bone mineral density (BMD), bone metabolism,
and body composition in 47 children with central precocious
puberty (n  36) or early puberty (n  11) before, during, and
after cessation of GnRH agonist. Bone density and body com-
position were measured with dual energy x-ray absorptiom-
etry and expressed as SD scores. Bone age and biochemical
parameters of bone turnover were assessed. Measurements
were performed at baseline, after 6 months, and on a yearly
basis thereafter.
Mean lumbar spine BMD SD scores for chronological age
were significantly higher than zero at baseline and decreased
during treatment. Lumbar spine bone mineral apparent den-
sity and total body BMD did not differ from normal at baseline
and showed no significant changes during treatment. In con-
trast, BMD SD scores for bone age were significantly lower
than zero at baseline and at cessation of therapy. Two years
after therapy, bone mineral apparent density and BMD SD
scores for bone age and chronological age did not differ from
normal. Markers of bone turnover decreased during treat-
ment, mainly in the first 6 months. Patients had increased
percentage of fat and lean body mass at baseline. After an
initial increase of percentage body fat during treatment, per-
centage body fat decreased and normalized within 1 yr after
cessation of treatment.
Our longitudinal analysis suggests that peak bone mass or
body composition will not be impaired in patients with pre-
cocious or early puberty after GnRH agonist therapy. (J Clin
Endocrinol Metab 87: 506–512, 2002)
PUBERTY IS CONSIDERED to be a crucial period forbone mass acquisition (1). Therefore, it is important to
know whether children with a disorder in pubertal devel-
opment will achieve an adequate peak bone mass (PBM).
In central precocious puberty (CPP), the hypothalamus-
pituitary-gonadal axis is activated before the age of 8 yr in
girls and before the age of 9 in boys. Treatment is based on
administration of GnRH agonist (GnRH-a), which inhibits
pituitary gonadotrophin secretion resulting in a decrease of
sex steroid levels (2). Estrogen deprivation, for instance after
ovariectomy or natural menopause, is associated with sig-
nificant bone loss in adult women (3). A significant decrease
in bone density during GnRH-a therapy in women with
endometriosis and in men with benign prostatic hyperplasia
has been reported (4, 5). Thus, reducing sex steroid levels in
CPP could have detrimental effects on bone density, and the
achievement of PBM particularly could be impaired.
Besides putative negative effects of GnRH-a on bone mass
acquisition, concern has been raised that children with CPP
are prone to development of adiposity (6, 7).
The aim of the present study was to evaluate longitudi-
nally bone mineral density (BMD), bone metabolism, and
body composition in a large group of children with preco-
cious or early puberty before, during, and after cessation of
GnRH-a treatment. Preliminary results were presented pre-
viously (8).
Subjects and Methods
Forty-seven patients (5 boys and 42 girls) were enrolled in the study.
The mean age at start of GnRH-a treatment was 8.3 yr (range, 2.8–11.4
yr). At diagnosis, all patients had a history of increased growth velocity,
girls had breast stage at least 2, boys had genital stage at least 2 and testes
volume at least 4 ml, bone age was advanced more than 1 yr, and a
GnRH-stimulated serum LH concentration was greater than 10 IU/liter.
Thirty-one children had idiopathic CPP with start of puberty before the
age of 9 yr for boys and before the age of 8 yr for girls. Five children had
organic CPP (two meningomyelocele, one hydrocephalus, one optic
glioma, and one craniopharyngeoma). Idiopathic early puberty was
found in 11 children, defined as appearance of pubertal signs between
8–10 yr of age for girls and between 9–11 yr of age for boys.
All patients were treated with depot leuprolide-acetate 3.75 mg (Lu-
crin Depot, Abbott Laboratories, Abbott Park, IL) given sc every 2 wk
in the first month and every 4 wk thereafter.
Pubertal suppression was evaluated by clinical evaluation, by re-
peating GnRH stimulation test after 3 months, by measuring basal serum
levels of LH, FSH, and E2 or T levels every 6 months of treatment. All
children had complete suppression of LH and FSH during the GnRH test
after 3 months of treatment (levels5 IU/liter). All patients, except one
boy and one girl, had complete suppression during therapy, with pre-
pubertal basal sex steroid concentrations (E2 50 pmol/liter; T 1
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nmol/liter). In the boy and girl with incomplete suppression, GnRH-a
dose was doubled, which resulted in complete suppression.
Anthropometry, assessment of biochemical parameters of bone turn-
over, and BMD and body composition measurements were performed
at baseline, after 6 months and 1 yr, and then yearly. All assessments
were continued after discontinuation of treatment on a yearly basis.
Forty patients completed treatment, of whom 38 agreed to continue
participation. Twenty patients (2 boys and 18 girls; 15 CPP and 5 early
puberty) had complete follow-up measurements from start of GnRH-a
therapy until 2 yr after cessation of treatment. This subgroup will be
described separately.
Height was measured with a Harpenden stadiometer and expressed
as sd score (9). Pubertal stage was assessed according to Tanner (10).
Bone age was scored by one investigator using an x-ray of the left hand
according to the Greulich and Pyle method (11).
Bone density and body composition
BMD of the lumbar spine (LS) and total body (TB) was measured by
dual energy x-ray absorptiometry (DEXA) (DPXL/PED, Lunar Corp.,
Madison, WI). The LS is mainly composed of trabecular bone, whereas
80% of the TB bone consists of cortical bone (12). To correct for bone size,
we calculated bone mineral apparent density (BMAD) of LS with the
model BMADLS  BMDLS  [4/(  width)]. This model has been
validated by in vivo volumetric data obtained from magnetic resonance
imaging of lumbar vertebrae (13). All children were measured by the
same apparatus. Quality assurance was performed daily. The coefficient
of variation has been reported to be 1.04% for spine BMD and 0.64% for
BMDTB (14). Body composition was measured by TB DEXA. BMD, bone
mineral content, lean tissue mass, and percentage body fat were com-
pared with our Dutch age- and sex-matched reference values (n  500;
age, 4–20 yr) (15, 16). One girl was too young (2.8 yr) to compare her
DEXA results with our normative data. Her data could be used to
calculate bone age-adjusted sd scores. In two children, baseline DEXA
measurement was not performed due to logistic reasons.
Biochemical parameters
Blood samples were obtained for the assessment of calcium (Ca),
anorganic phosphate, and 1,25-dihydroxyvitamin D. Furthermore, al-
kaline phosphatase (ALP) and procollagen type I C-terminal propeptide
(PICP) were assessed as markers of bone formation, whereas carboxy-
terminal telopeptide of type I collagen (ICTP) and urinary hydroxypro-
line (OHP) concentration were measured as markers of bone resorption.
1,25-Dihydroxyvitamin D was measured by RIA of Immuno Diagnostics
Systems (Boldon, UK). RIA kits (Orion Diagnostica, Espoo, Finland)
were used for measurement of PICP and ICTP. ALP, phosphate, PICP,
and ICTP were expressed as sex- and age-matched sd scores using our
own reference values. E2 and T were assessed by RIA (Orion Diag-
nositica); LH and FSH by RIA (MedGenix Diagnositics, Fleurus, Bel-
gium). The Ca/creatinine (Cr) ratio and OHP concentration, expressed
as mmol/mol Cr (OHP/Cr), were assessed in the first morning void of
urine. Written informed consent was obtained from the parents of the
patients.
Statistical analysis
One-sample t tests were used to compare the mean sd scores with the
expected zero, which is the mean sd score of age- and sex-matched
healthy controls. The within-patient change was tested using a paired
t test. To test differences between patients with early puberty and pre-
cocious puberty, Mann-Whitney U tests were used. Pearson’s correlation
coefficient was used to test the association between two variables with
a normal distribution, and Spearman’s correlation was used in case of
a skewed distribution. In view of multiple tests, the significance level
was set at P  0.01.
Results
Bone density and body composition before treatment
Clinical baseline characteristics are reported in Table 1.
The results of BMD and body composition before and during
treatment for all patients are shown in Table 2. At baseline,
mean BMDLS sd score was significantly higher than zero.
BMADLS and BMDTB sd scores were above normal, but this
did not reach significance. However, after correction for bone
age instead of chronological age, BMDLS and BMDTB sd
scores corrected for bone age were significantly lower than
zero. BMADLS sd score corrected for bone age was normal.
Height, bone mineral content, percentage fat, lean body
mass (LBM), and body mass index (BMI) sd scores (all sd
scores for chronological age) were significantly increased at
baseline.
Forty patients completed treatment; their mean treatment
period was 2.7 yr (range, 1.4–5.4 yr). After an initial increase,
TABLE 1. Clinical characteristics at baselinea
Boys Girls
No. 5 42
Age (yr) 9.0 (4.7  11.4) 8.2 (2.8  10.8)
Bone age (yr) 11.9 (9.2  14.5) 10.7 (4.3  13.3)
Height SD score 0.39 (1.96  2.09) 0.80 (1.77  4.71)
BMI SD score 0.63 (0.47  2.79) 1.17 (0.76  2.80)
a Mean (range).
TABLE 2. Mean height, BMD, and body composition expressed as SD scores (SEM) in children with precocious puberty at baseline and
during GnRH-a treatment
Time
No.
Baseline
44
0.5 yr
45
1 yr
45
2 yr
39
3 yr
24
SD score for chronological age
BMDLS 0.67 (0.18)
b 0.83 (0.16)b,1 0.65 (0.17)b 0.48 (0.18) 0.39 (0.25)
BMADLS 0.36 (0.18) 0.50 (0.16)
a 0.41 (0.17) 0.38 (0.18) 0.05 (0.22)
BMDTB 0.19 (0.19) 0.39 (0.19) 0.50 (0.17)
a,1 0.38 (0.19) 0.31 (0.27)
SD score for bone age
BMDLS 0.54 (0.15)
b 0.57 (0.14)b 0.36 (0.18) 0.29 (0.22)
BMADLS 0.15 (0.18) 0.20 (0.17) 0.06 (0.19) 0.29 (0.25)
BMDTB 0.85 (0.15)
b 0.64 (0.14)b,2 0.40 (0.17)2 0.39 (0.24)1
SD score for chronological age
LBM 0.92 (0.21)b 0.79 (0.20)b,1 0.71 (0.20)b,1 0.49 (0.25)2 0.31 (0.33)1
Percentage body fat 0.47 (0.18)a 0.98 (0.18)b,2 1.28 (0.18)b,2 1.30 (0.21)b,2 1.10 (0.26)b,2
Height 0.75 (0.20)b 0.65 (0.22)a 0.55 (0.22)1 0.53 (0.23)2 0.18 (0.37)2
BMI 1.11 (0.13)b 1.24 (0.13)b 1.46 (0.13)b,2 1.47 (0.17)b,2 1.22 (0.21)b
a P  0.01, b P  0.001 for the comparison of the mean SD score with zero.
1 P  0.01, 2 P  0.001 compared with baseline.
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BMDLS and BMDTB, corrected for chronological age, tended
to decrease (Table 2). BMADLS showed the same trend, but
these changes were not significant. However, when adjusted
for bone age, BMDTB sd scores for bone age increased sig-
nificantly during treatment. As for chronological age, no
significant changes in BMADLS corrected for bone age were
found during treatment. BMDLS sd scores for bone age also
did not change during treatment.
Percentage body fat sd scores increased, and LBM sd
scores decreased significantly (Table 2). Height sd scores
decreased; after 1 yr of treatment height sd scores did not
differ significantly from zero any more. BMI sd scores in-
creased significantly during treatment.
Results of 20 patients followed from start to 2 yr after
cessation of therapy
Figure 1 shows bone density and body composition before,
at cessation of GnRH-a treatment, and 2 yr after cessation of
treatment in 20 patients who were followed for this entire
period. For this particular subgroup, mean (sd) age and bone
age at start was 8.7 (1.1) and 11.3 (1.24) yr, respectively. Mean
(sd) age at cessation of therapy was 11.3 (0.8) yr. Mean (sd)
bone age was 12.4 (0.7) yr at cessation of therapy, and 14.6
(1.0) yr at 2 yr after cessation of therapy. Mean treatment
period for this subgroup was 2.6 yr (range, 1.4–4.1 yr).
At baseline, BMDLS sd score adjusted for chronological age
was 0.54 (sd  1.15; P  0.06). BMDLS sd scores for chro-
FIG. 1. BMD adjusted for chronologi-
cal age (top) and bone age (bottom) be-
fore start, at cessation, and after cessa-
tion of GnRH-a therapy in children with
precocious and early puberty [mean
(SEM)]. a P  0.01, b P  0.001 for the
comparison of the mean SD score with
zero; *, P 0.01, **, P 0.001 compared
to stop.
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nological age decreased significantly during treatment,
whereas BMDTB and BMADLS sd scores showed no signif-
icant change. After cessation of therapy, no significant
changes in bone density were found (Fig. 1, top).
After correction for bone age (Fig. 1, bottom), only BMDTB
showed a significant increase, whereas BMADLS and BMDLS
did not change during treatment. BMDLS and BMDTB re-
mained significantly lower than zero at cessation of treat-
ment. After cessation of GnRH-a therapy, all three bone
density parameters slightly increased compared with stop of
therapy. After 2 yr, none of the bone density parameters
differed from zero any more.
The mean absolute change between start and cessation of
GnRH-a therapy was 0.09 g/cm2 for BMDLS and BMDTB and
0.01 g/cm3 for BMAD. None of the children had an absolute
decrease in BMD during therapy. Most children showed an
absolute increase in BMAD as well, but in three children a
decrease in BMAD (0.01–0.02 g/cm3) was found. In the 2 yr
after cessation of therapy, BMD and BMAD showed an ab-
solute increase in all children.
LBM decreased significantly during treatment, and per-
centage body fat increased (Fig. 2). After cessation of treat-
ment, LBM and height showed a further decrease, whereas
percentage body fat decreased to pretreatment values. Al-
though BMI decreased significantly after treatment was
stopped, it remained significantly higher than zero after
treatment. Two years after cessation of therapy, LBM, per-
centage body fat, and height sd scores did not differ signif-
icantly from zero.
Biochemical parameters
Table 3 shows the results of biochemical parameters at
baseline, during treatment, and after cessation of treatment.
Only baseline and 6-month data are given, because the sub-
stantial changes were found in this period. During GnRH
treatment, serum Ca was normal and remained stable. At
baseline, ICTP sd score was significantly higher than zero.
PICP sd score was also increased, but in a lesser degree (P
0.03). Mean phosphate sd scores, ALP sd scores, 1,25-dihy-
droxyvitamin D, and Ca/Cr ratio were normal. Urine OHP
concentration was in the high reference range. ALP, ICTP,
and PICP sd scores and urine Ca/Cr ratio decreased signif-
icantly during treatment, mainly in the first 6 months, and
stabilized thereafter. Phosphate sd scores showed a slight
decrease. Urinary OHP concentration decreased signifi-
cantly during treatment.
At cessation of therapy, all serum markers, except Ca and
1,25-dihydroxyvitamin D, were decreased compared with
baseline. Phosphate, PICP, and ALP sd scores were signifi-
cantly lower than zero at cessation of treatment.
After cessation of therapy, ALP, PICP, and ICTP increased
with a subsequent decrease. Two years after treatment, ALP
and PICP sd scores for chronological age were significantly
lower than zero. After correction for bone age, however,
normal sd scores were found. Urine OHP concentration
showed an ongoing decrease, whereas urine Ca/Cr ratio did
not change.
Precocious puberty vs. early puberty
The mean treatment period was 2.8 yr in the CPP patients
and 2.2 yr in patients with early puberty. Patients with CPP
had higher height and LBM sd scores than children with
early puberty at baseline and at cessation of treatment. No
differences in BMI and percentage body fat were found. At
baseline, BMD and BMAD for chronological age and bone
age did not differ. BMDTB and BMDLS for chronological age
were significantly higher in the CPP group at cessation of
therapy. BMAD and BMD for bone age did not differ at
cessation of treatment.
Correlations
The changes () between values at cessation of treatment
and at start of treatment were calculated.Height andLBM
sd scores were positively correlated with BMDLS (r  0.46,
P  0.007; r  0.61, P  0.001, respectively), but not with
FIG. 2. Body composition and height
adjusted for chronological age [mean
(SEM)] at start, at cessation, and after
cessation of GnRH-a therapy in chil-
dren with precocious puberty. a, P 
0.01; b, P  0.001 for the comparison of
the mean SD score with zero; *, P 0.01,
**, P  0.001 compared to stop.
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BMADLS or BMDTB. BMI sd score was not significantly
correlated with BMD or BMAD sd scores. Changes in
parameters of bone turnover showed correlation with neither
height sd scores nor changes in BMD or BMAD sd scores.
Discussion
The present study showed increased BMDLS for chrono-
logical age in children with precocious or early puberty.
During GnRH-a treatment, BMD and BMAD of lumbar spine
and total body BMD for chronological age decreased, after an
initial increase, to the normal range. However, after correc-
tion for bone age, BMDLS and BMDTB were reduced. Using
BMADLS (volumetric or apparent BMD) corrected for bone
age normal bone density before, during, and after cessation
of treatment was found.
Sex steroids, and especially estrogens, are very important
in the acquisition of bone mass. This became more clear when
two new syndromes were described, each representing a
human model in which estrogen was lacking. A female with
aromatase deficiency (17) and a male with ER defect (18) had
severe undermineralization of the skeleton and no epiphy-
seal closure. So, androgens do not cause normal epiphyseal
closure and bone mineralization in the absence of estrogens.
In GnRH-a-treated precocious puberty, a decrease in sex
steroids by GnRH-a may explain the decrease in bone den-
sity. The initial increase in BMD in our patients may be
explained by incomplete suppression of puberty during the
first months.
In children with growth disorders, BMAD may be a
more appropriate parameter to evaluate bone mineraliza-
tion than (areal) BMD. Because children with precocious
puberty have tall stature, BMD measured by DEXA will be
overestimated. By calculating BMAD, a correction for bone
size is made. Indeed, BMAD was increased to a much
lesser extent than BMDLS. Together, these findings suggest
that increased BMDLS and increased bone turnover at
baseline mainly reflect increased growth, rather than in-
creased bone mineralization.
In adults with GnRH-a therapy, an absolute decrease in
BMD has been reported (4, 5). In contrast, absolute BMD
increased during GnRH-a therapy in children, albeit at lower
rates than before start of therapy, because their sd scores
decreased. Adults reach their PBM and will not further in-
crease their bone mass in physiological conditions. Absolute
BMD also increases in healthy prepubertal children who are
not exposed to high levels of sex steroids. This might explain
that during gonadal suppression in our CPP patients BMD
continued to increase.
Heger et al. (19) studied patients after cessation of GnRH-a
therapy at final height. These young women had normal
bone density of LS and femoral neck. Most studies found a
BMD high for chronological age, but appropriate for bone
age (19–21), before start of therapy. The described effects of
GnRH-a on bone are still controversial. No change during 2
yr of treatment has been reported (20), as well as a decrease
in trabecular bone density during GnRH-a therapy, whereas
cortical bone of the radius did not change (22). Saggese et al.
(23) reported a reduction in BMD in cortical bone of the
radius within 6 months. Most studies were performed in
rather small patient groups varying from 10–13 children.
Additionally, differences in reference values and differences
in site, which have been measured, and differences in timing
of start of treatment may have contributed to some of the
discrepancy with our results. Furthermore, our study also
included children with early puberty. Children with CPP
were taller but did not have higher BMD than children with
early puberty, at baseline. Despite a somewhat longer treat-
ment in CPP, BMD was even somewhat higher in CPP at
cessation of therapy. This difference disappeared after cor-
rection for bone size by calculating BMAD. Bertelloni et al.
(24) stated that PBM was not impaired in girls treated with
GnRH-a. Because PBM of LS was measured at the chrono-
logical age of 13.4 yr, this might have been too early. Bone
mineral accrual continues in the postpubertal years after
linear growth has ceased. Furthermore, the age that PBM is
reached appeared to be site-dependent (25). Our patients had
mean age of 13.4 yr and bone age of 14.7 yr at their last visit.
Theoretically, children with precocious puberty might attain
their PBM at an earlier chronological age, because of their
advanced bone maturation. However, all patients showed an
ongoing increase in BMDLS after cessation of therapy. So, we
cannot draw any final conclusions yet regarding PBM. None-
theless, our findings, e.g. normal bone mass and bone turn-
over 2 yr after cessation of therapy, do not suggest that PBM
will be impaired in children with a history of GnRH-a
therapy.
We found that the ICTP was significantly higher and PICP
was slightly higher than normal before the start of treatment.
TABLE 3. Biochemical parameters at baseline and after cessation of GnRH agonist treatment in children with precocious puberty
[mean (SEM)]
Before and during GnRH-a After cessation of GnRH-a
Baseline 6 months Stop 1 yr 2 yrs
No. 45 44 33 29 18
Ca (mmol/liter) 2.42 (0.02) 2.42 (0.02) 2.38 (0.02) 2.37 (0.02) 2.39 (0.03)
Phosphate SD score 0.07 (0.11) 0.23 (0.12) 0.23 (0.08)** 0.13 (0.15) 0.33 (0.17)
ALP SD score 0.10 (0.19) 1.05 (0.15)b,** 1.18 (0.24)b,** 0.56 (0.26)1 1.48 (0.44)a
PICP SD score 0.57 (0.25) 0.74 (0.21)a,** 1.23 (0.19)b,** 0.45 (0.29) 1.11 (0.26)b
ICTP SD score 1.78 (0.14)b 0.26 (0.14)** 0.03 (0.32)** 0.68 (0.23)a 0.48 (0.33)
1,25-dihydroxyvitamin D (pmol/liter) 132.1 (7.0) 125.1 (7.1) 117.5 (5.7) 138.4 (6.4)1 129.6 (7.8)
Urine Ca/Cr ratio 0.20 (0.02) 0.40 (0.04)* 0.33 (0.03)* 0.24 (0.05) 0.28 (0.06)
Urine OHP/Cr ratio (mmol/mol) 132 (9) 104 (16)** 77 (4)** 86 (9) 52 (5)1
a P  0.01, b P  0.001 for the comparison of the mean SD score with zero; *, P  0.01, **, P  0.001 compared with baseline; 1 P  0.01,
2 P  0.001 compared to stop.
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During treatment, bone turnover decreased mainly in the
first 6 months of treatment and stabilized thereafter. Other
authors found similar results. Antoniazzi et al. (22) showed
that patients with CPP had pubertal osteocalcin levels that
decreased during treatment. Hertel et al. (26) reported that
girls with CPP had normal PICP levels that decreased within
2 months after initiation of GnRH-a and remained below
baseline values. Therefore, markers of bone resorption as
well as markers of bone formation decrease during GnRH-a
therapy. However, biochemical markers are not specific for
bone modeling or remodeling. Additionally, PICP, ICTP, and
ALP are not bone-specific. Thus, changes in biochemical
markers may reflect changes in growth as well as changes in
bone mineralization. Two years after cessation of therapy,
the markers of bone turnover were in the normal range for
bone age.
Obesity is a common problem in children with precocious
puberty (6, 27, 28). Indeed, in the present study, percentage
body fat was increased at baseline. At cessation of therapy,
percentage body fat was significantly higher than normal,
and it normalized thereafter. After an initial aggravation of
adiposity, no prolonged negative effects on percentage body
fat were found. In concordance with our study, two other
studies showed increased BMI at the start but no change in
BMI during treatment (6, 19). BMI cannot distinguish be-
tween LBM and fat mass; BMI will not change when LBM
decreases and fat mass increases as occurred in our study.
Therefore, DEXA is preferred to evaluate body composition.
The decreased GH and IGF-I levels that have been re-
ported during GnRH-a therapy (27, 29, 30) might play a role
in the increment of fat mass and decrease in LBM. Kamp et
al. (27) showed that GH levels in GnRH-a-treated children
with CPP were inversely related to BMI. GH-deficient pa-
tients have decreased bone density, increased fat mass, and
decreased LBM, which improved during GH replacement
therapy (31). Besides a decrease in estrogens and GH levels,
the decrease in muscle mass during GnRH-a therapy may
also affect bone mineralization.
In conclusion, children with precocious and early puberty
had normal total body BMD and increased BMDLS for chro-
nological age. Only BMDLS decreased significantly during
GnRH-a therapy. In contrast, BMD corrected for bone age
was significantly lower than normal. Using BMADLS (volu-
metric or apparent BMD) corrected for chronological age or
bone age, normal bone density before, during, and after
cessation of treatment was found. Two years after cessation
of therapy, bone density for bone age and chronological age
did not differ from normal, and markers of bone turnover
adjusted for bone age were normal. Thus, this study suggests
that PBM will not be impaired in children with a history of
GnRH-a therapy. However, our patients did not reach their
PBM yet, so further follow-up is still needed. After an initial
aggravation of adiposity during treatment, their percentage
body fat decreased to normal values after treatment was
stopped.
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Asymptomatic Primary Hyperparathyroidism
National Institute of Diabetes and Digestive and Kidney Diseases
National Institutes of Health
Bethesda, Maryland
April 8–9, 2002
A 1990 NIH Consensus Development Conference on Asymptomatic Primary Hyperparathyroidism, spon-
sored by NIDDK, explored the causes and effects of this disease, developing a consensus on how to treat
it. Together with a research agenda, the consensus statement provided landmarks for basic and clinical
approaches to the disease. Since then, many new advances have occurred, in many instances providing new
approaches to treatment.
Now in 2002, this workshop will attempt to define the current state of the art by focusing on the latest basic
and clinical advances that have been made in our understanding of this disease, with an eye on identifying
new directions for the 21st century. Posters are welcome.
For further information, call (301) 493-9674, ext. 104, or visit the meeting website (www.phpt.niddk.nih.gov).
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